CareFusion Corp. (CFN) entered into a multi-year technology licensing agreement with Masimo Corp. (MASI) regarding the use of Masimo Rainbow SET Pulse CO-Oximetry technology in CareFusion infusion and respiratory products, which are presently under development.    The agreement enables CareFusion’s future infusion and respiratory products to non-invasively and continuously measure multiple blood constituents to more accurately assess dyshemoglobins affecting oxygenation, predict fluid responsiveness, and provide earlier identification of respiratory compromise.   CareFusion’s ventilators and infusion pumps facilitate earlier detection, diagnosis and treatment of potentially life-threatening conditions by accessing total hemoglobin (SpHb), oxygen content (SpOC), carboxyhemoglobin (SpCO), methemoglobin (SpMet), and PVI for fluid responsiveness, in addition to oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate.   CareFusion is a medical technology company formed recently by the spin-off of the Clinical and Medical Products business of Cardinal Health, Inc. (CAH). The spin-off was completed in September ...

Masimo Corporation (MASI) reported third quarter fiscal 2009 results. Earnings per share were 22 cents, beating the Zacks Consensus Estimate of 21 cents. However, earnings were flat year over year.  Total revenues in the reported quarter increased roughly 12% year over year to $87.4 million. Product revenues increased 14% year over year to $75.1 million. Royalty revenues increased roughly 2% year over year to $12.3 million. Growth in product revenue can be attributed to higher demand for Masimo SET and Masimo Rainbow SET monitors.  Masimo SET revenues increased approximately 10% year over year to $69.1 million as a result of an expansion in the company’s client base of hospitals. Masimo Rainbow SET revenues doubled year over year to $6.0 million. Growth can be primarily attributed to strong demand for Rainbow licensed parameters, especially SpCO and SpHb, and higher sale of Rainbow consumables.  Gross margin in ...

Alcon, Inc. (ACL) recently entered into an in-licensing agreement with Potentia Pharmaceuticals, a privately-held biotechnology company that focuses on the development of medicines for the treatment of age-related macular degeneration (AMD). Alcon gained the right to develop Potentia's leading drug candidate, POT-4, for the treatment of AMD. Alcon also gained the right to acquire Potentia’s shares on the achievement of certain development milestones and if Alcon opts to continue with the development of POT-4.   Alcon will make upfront payments to Potentia for the initial license and option rights. Potentia is also entitled to receive future payments based on the achievement of several clinical and global regulatory approval milestones for different therapeutic indications and on Alcon's decision to proceed with development. Potentia will also receive royalties based on sales of any products that are approved and commercialized under this agreement.   POT-4 is a complement inhibitor, which is ...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday October 19, 2009

DrStockPick.com Stock Report!

AMLN, PWRM, MMM, CSRH, MYL, CVAT, STEM, AQNM

**************************************************************

AMLN, Amylin Pharmaceuticals, Inc.

AMLN is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines.

AMLN will webcast its Quarterly Update Conference Call for the third quarter of 2009 on Tuesday, October 20, 2009 at 5:00 p.m. ET/2:00 p.m. PT. Daniel M. Bradbury, Amylin’s president and chief executive officer, will lead the call. On the same date post-market, Amylin will release financial results for the third quarter of 2009.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a

...

This post provides links to a number of interesting articles I have read over the past few days that you may also enjoy.

• Doug Kass (TheStreet.com): Madman at the gates, September 29, 2009. Despite the strong share price momentum and optimistic economic/profit consensus, I continue to hold on to the variant view that the markets have likely peaked for the year based on the existence of nontraditional headwinds, an end to decades of aggressive credit expansion and financial inventiveness, a still-vulnerable housing recovery (in the form of outsized phantom inventory challenges) and a still-fragile consumer — among other factors.

• Joshua Zumbrun (Forbes): Reasons to remain wary about housing, September 29, 2009. After signs of life this summer, here are eight factors to watch that could extend the bust.

• Tim Duy (Tim Duy’s Fed Watch): Rushing to the

...

Last week, Regeneron Pharmaceuticals, Inc. (REGN) announced the completion of enrollment in two late stage studies of its VEGF (vascular endothelial growth factor) trap-eye treatment for age-related macular degeneration (wet AMD), a leading cause of blindness in adults. Each of the randomized, double-masked trials has enrolled more than the target of 1,200 patients. The company is developing the drug in partnership with Bayer HealthCare (BAYRY.PK). The study will be a non-inferiority comparison of the VEGF trap-eye with ranibizumab (Lucentis from Genentech, Inc- now a wholly owned subsidiary of the Roche group (RHHBY.PK)), an anti-angiogenic agent approved for use in wet AMD. The company expects one-year primary endpoint data from both studies in the fourth quarter of 2010. As a reminder, Regeneron and Bayer HealthCare entered into a collaboration agreement in Oct 2006 for the development and commercialization of the VEGF trap-Eye outside ...

Masimo Corporation (MASI) announced that it has signed a new worldwide technology licensing agreement with GS Elektromedizinische Gerate G. Stemple GmbH that will enable the latter to integrate Masimo’s Rainbow SET Pulse CO-Oximetry into its corpuls patient monitoring modules. GS Elektromedizinische Gerate G. Stemple GmbH is a leading German company that develops and manufactures innovative medical equipment for Emergency Medical Services (EMS) and intensive care. The company is a market leader in providing innovative EMS solutions throughout Europe. The company’s corpuls patient monitoring modules and defibrillators are used in the first aid treatment of patients suffering from sudden cardiac arrest. Masimo’s Rainbow SET Pulse CO-Oximetry allows for continuous monitoring of hemoglobin, carbon monoxide, methemoglobin, PVI for fluid responsiveness, perfusion index and measure-through motion pulse oximetry. The integration of the Rainbow SET Pulse CO-Oximetry will enhance the efficiency of GS GmbH’s defibrillators and patient monitoring systems ...

At last, the uncertainty regarding Sanofi-Aventis' (SNY) Lantus (generic name insulin glargine) seems to be over. Today, the company released a statement by a board of experts regarding the potential link of Lantus with increased cancer risk. They have come to the conclusion that all the four cases had significant methodological limitations and shortcomings, thus making the results inconclusive.

As a reminder, in the month of June, a study by the European Association for the Study of Diabetes observed that Lantus (generic name insulin glargine) increases the risk of cancer in diabetics taking the drug. The study, carried out on 127,000 patients in four European countries found that out of every 100 patients using Lantus for about 1 1/2 years, one additional person developed cancer.

But the FDA was not convinced with the study as patients were not studied long enough to substantiate the risk. Accordingly, it planned to review the

...

Masimo Corporation's (MASI) Q109 results were strong, with solid revenue and EPS growth. In our recent report on the company, we note the current price trades at a P/E/G multiple of 1.3x for 2009, greater than both the industry mean and the comparables' mean P/E/G multiple of 1.2x.The company's stock deserves to trade at a 15% premium to the comparables' mean P/E/G multiple. This equates to a P/E of 28.7x and a target price of approximately $25.55. We reiterated our 'Hold' rating for this stock.MASI develops, manufactures and markets a family of non-invasive blood monitoring systems that consist of a monitor, circuit board and sensors. The systems are primarily used to monitor blood oxygen saturation levels and protect against hypoxemia and hyperoxemia. (Hypoxemia, low blood-oxygen levels, can result in brain damage and death. Hyperoxemia, high-blood oxygen levels, can result in permanent eye-damage ...

Perception and reality are not the same thing. And believing they are is a very dangerous for investors. Why? Because you can very easily fall into the trap of “market blindness” – you can assume you see everything while missing the elephant in the room.

Before you ask, we haven’t been smoking something strange here at the Notes office. We’ve been reading Justice Litle’s fascinating essay on trader psychology in today’s Taipan Daily. And we figure contains an important lesson for underground investors.

Justice says a famous experiment by a group of Harvard psychologists reveals big “holes” in human perception, especially when we are concentrating hard on a task. The psychologists asked a group of test subjects to pass a basketball back and forth between players dressed in black and those dressed in white. All they were asked to do was count the number of passes between the two teams.

The psychologists

...